Drug Profile
Zinc finger protein-based gene therapy - Pfizer/Sangamo Therapeutics
Alternative Names: C9ORF72 ZFP-TF; ZFP TF gene therapy; ZFP-based therapeutics - Sangamo/Pfizer; ZFP-TF gene therapies; Zinc finger protein gene therapy - Pfizer/Sangamo; Zinc finger protein gene therapy - Sangamo/Pfizer; Zinc finger protein transcription factors - Sangamo/PfizerLatest Information Update: 17 Aug 2020
Price :
$50
*
At a glance
- Originator Sangamo Therapeutics
- Developer Pfizer; Sangamo Therapeutics
- Class Antidementias; Gene therapies; Neuroprotectants; Transcription factors; Zinc finger DNA binding proteins
- Mechanism of Action Genetic transcription modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Dementia
Most Recent Events
- 17 Aug 2020 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral), prior to August 2020 (Sangamo Therapeutics pipeline, August 2020)
- 17 Aug 2020 Preclinical trials in Dementia in USA (Parenteral), prior to August 2020 (Sangamo Therapeutics pipeline, August 2020)
- 03 Jan 2018 Early research in Amyotrophic lateral sclerosis in USA (Parenteral)